Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

Early diagnosis of neurodegenerative disorders such as Alzheimer's (AD) or Parkinson's disease (PD) is needed to slow down or halt the disease at the earliest stage. Cerebrospinal fluid (CSF) biomarkers can be a good tool for early diagnosis. However, their use in clinical practice is challenging due to the high variability found between centers in the concentrations of both AD CSF biomarkers (Aβ42, total tau and phosphorylated tau) and PD CSF biomarker (α-synuclein). Such a variability has been partially attributed to different preanalytical procedures between laboratories, thus highlighting the need to establish standardized operating procedures. Here, we merge two previous consensus guidelines for preanalytical confounding factors in order to achieve one exhaustive guideline updated with new evidence for Aβ42, total tau and phosphorylated tau, and α-synuclein. The proposed standardized operating procedures are applicable not only to novel CSF biomarkers in AD and PD, but also to biomarkers for other neurodegenerative disorders.

[1]  R. Sakakibara,et al.  Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease , 2012, Alzheimer disease and associated disorders.

[2]  B. Mollenhauer,et al.  Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. , 2012, Methods.

[3]  G. Borm,et al.  Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers , 2012, Neurobiology of Aging.

[4]  R. Nussbaum,et al.  Basic Neurosciences, Genetics and Immunology -original Article A-synuclein in Human Cerebrospinal Fluid Is Principally Derived from Neurons of the Central Nervous System , 2022 .

[5]  M. Albert,et al.  Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. , 2012, Archives of neurology.

[6]  Leslie M. Shaw,et al.  Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2012, Alzheimer's & Dementia.

[7]  M. Verbeek,et al.  CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans , 2011, Neuroscience Letters.

[8]  J. Molinuevo,et al.  Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ß-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas , 2011, Biological Psychiatry.

[9]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[10]  P. Calabresi,et al.  Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias , 2011, Movement disorders : official journal of the Movement Disorder Society.

[11]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[12]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[13]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[14]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[15]  O. Laterza,et al.  Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[16]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[17]  M. Blankenstein,et al.  Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop , 2010, International journal of Alzheimer's disease.

[18]  G. Waldemar,et al.  Proteomic investigations of the ventriculo-lumbar gradient in human CSF , 2010, Journal of Neuroscience Methods.

[19]  K. Blennow,et al.  Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid , 2010, International journal of Alzheimer's disease.

[20]  K. Blennow,et al.  Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease , 2010, Alzheimer's & Dementia.

[21]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[22]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[23]  W. M. van der Flier,et al.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.

[24]  Jun Wang,et al.  Alzheimer’s disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications , 2010, Experimental Gerontology.

[25]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[26]  Dominique Drouin,et al.  Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression , 2010, Alzheimer's & Dementia.

[27]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[28]  T. Hankemeier,et al.  The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). , 2009, Journal of proteome research.

[29]  F. Betsou,et al.  [Preanalytical guidelines for clinical proteomics investigation of biological fluids]. , 2009, Annales de biologie clinique.

[30]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[31]  C. Teunissen,et al.  Endogeneous peptide profiling of cerebrospinal fluid by MALDI‐TOF mass spectrometry: Optimization of magnetic bead‐based peptide capture and analysis of preanalytical variables , 2007, Proteomics. Clinical applications.

[32]  Fotini Betsou,et al.  Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation , 2007, Clinical chemistry and laboratory medicine.

[33]  O. Kvalheim,et al.  Pre‐analytical influence on the low molecular weight cerebrospinal fluid proteome , 2007, Proteomics. Clinical applications.

[34]  P. Thomann,et al.  Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1–42) , 2007, Neuroscience Letters.

[35]  J. Morris,et al.  Fluctuations of CSF amyloid-β levels , 2007, Neurology.

[36]  Michael J. Pikal,et al.  Protein Stability During Freezing: Separation of Stresses and Mechanisms of Protein Stabilization , 2007, Pharmaceutical development and technology.

[37]  P. Lewczuk,et al.  International quality control survey of neurochemical dementia diagnostics , 2006, Neuroscience Letters.

[38]  M. S. Benfato,et al.  Serum S100B protein is increased in fasting rats. , 2006, Archives of medical research.

[39]  M. Plebani.  Errors in clinical laboratories or errors in laboratory medicine? , 2006, Clinical chemistry and laboratory medicine.

[40]  O. Prospero-Garcia,et al.  Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. , 2006, Life sciences.

[41]  J. D. del Río,et al.  Reelin expression and glycosylation patterns are altered in Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Juan Manuel Maler,et al.  Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. , 2006, Clinical chemistry.

[43]  E. Marchiori,et al.  Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.

[44]  Jean-Charles Sanchez,et al.  Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process? , 2005 .

[45]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[46]  P. Lewczuk,et al.  Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides , 2004, Electrophoresis.

[47]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[48]  J. Vente,et al.  Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid , 2002, Neurobiology of Aging.

[49]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[50]  T. Pollmächer,et al.  Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy , 2001, Annals of neurology.

[51]  H. Reiber,et al.  Dynamics of brain-derived proteins in cerebrospinal fluid. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[52]  Hansotto Reiber,et al.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs , 2001, Journal of the Neurological Sciences.

[53]  J. Stevens,et al.  Post‐lumbar puncture headaches , 1992, Neurology.

[54]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[55]  H. Vanderstichele,et al.  Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. , 2012, Journal of Alzheimer's disease : JAD.

[56]  S. Mandel,et al.  From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[57]  David Bartrés-Faz,et al.  Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[58]  D. Aarsland,et al.  A novel blood test for the early detection of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[59]  P. Lewczuk,et al.  Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. , 2011, Journal of Alzheimer's disease : JAD.

[60]  F. Jessen,et al.  Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. , 2011, Journal of Alzheimer's disease : JAD.

[61]  Axel Petzold,et al.  Spectrophotometry for cerebrospinal fluid pigment analysis , 2006, Neurocritical care.

[62]  P. Scheltens,et al.  Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. , 2005, Clinical chemistry.

[63]  Mu Wang,et al.  The impact of blood contamination on the proteome of cerebrospinal fluid , 2005, Proteomics.

[64]  K. Blennow,et al.  Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[65]  K. Blennow,et al.  Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. , 1993, European neurology.